In patients with COVID-19 pneumonia, an immune-mediated “cytokine storm” is believed to lead to acute respiratory failure and death. The CORIMUNO-19 platform was swiftly designed and set up to evaluate the efficacy and tolerance of various immune modulators and other treatments in adult patients with severe COVID-19 infection with series of multicenter randomized controlled trials that started March 27, 2020. This report pertains to a multicenter open-label randomized controlled trial of tocilizumab, a monoclonal antibody blocking the receptor for the interleukin-6 cytokine, used clinically in particular in the treatment of rheumatoid arthritis.

To read the full artcile, click here.